Clinical Research Directory

Inclusion Criteria: 1. Provision of signed and dated informed consent form; 2. Stated willingness to comply with all study procedures and availability for the duration of the study; 3. Age 18-64 years inclusive; 4. A minimum of one clinically significant common wart (usually found on hands, knees and elbows), or one plantar wart. Note: the warts for treatment cannot be a mixture of common and plantar warts; 5. Subject's common warts must measure between 3mm-10mm or for plantar warts, measure between 3mm-20mm, inclusive; 6. If currently receiving treatment for common or plantar warts, agree to stop their current medication for at least 28 days prior to the start of study treatment; 7. Agrees to refrain from using any other wart removal products or treatments during the study period; 8. Agrees to not take any non-steroidal anti-inflammatory drugs (NSAIDs) or antihistamines within a 12-hour period prior to and after randomized treatment; 9. Able to perform study assessments. Exclusion Criteria: 1. Pregnancy or breast feeding; 2. Mosaic warts for treatment; 3. Warts (common or plantar) that have been reported by the subject as present for more than 5 years (relates to any wart present and which may not necessarily be treated in this study); 4. Warts for treatment on areas of thin or sensitive skin as determined by the Investigator, e.g., face, neck, armpits, breasts, buttocks or genitals; 5. Areas for treatment where the skin is irritated, reddened or showing any sign of inflammation (e.g. itching and swelling); 6. Warts for treatment with hair growth, birthmarks, dark moles, pigmented skin or any other unusual skin condition; 7. History of infection in designated treatment area within 90 days prior to first treatment; 8. Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable electronic devices; 9. Metal implants at site of treatment (within foot or ankle); 10. Known allergy or intolerance to microwave therapy and cryotherapy; 11. Unstable co-morbidities (cardiovascular disease, active malignancy, inflammatory arthritis); 12. Participating in another interventional study or have done so within the last 30-days; 13. Anticipated relocation or extensive travel outside of the local study area preventing compliance with study procedures; 14. Circulatory conditions affecting the acral areas - peripheral vascular disease, peripheral ischemia, vasculitis, Raynaud's, or related conditions; 15. Peripheral neuropathy; 16. Subject with known immunosuppression disorders through illness or medication (for example - corticosteroids, biologic agents, methotrexate, ciclosporin); 17. Subject with autoimmune disease; 18. Diabetes (Type I or II); 19. History of vascular interventions to the legs, deemed as an unacceptable risk by the Investigator; 20. Prior dissection of axillary lymph nodes (for treated hand) or inguinal lymph nodes (for treated feet); 21. Dependent lymphedema; 22. Congestive heart failure; 23. History of repeated cellulitis (2 or more episodes); 24. History of deep venous thrombosis; 25. Subject currently receiving prescribed blood thinning medication; 26. Subject who has ever had any topical metallic treatment (e.g, aluminum chloride, silver nitrate) within the past year.